Radiotherapy result in tumor cell death by creating an immune potentiation effect, but can also lead to long lasting immune suppression. Thus the investigators hypothesize that pelvic and/or para-aortic radiotherapy for cervical cancer affects local tumor immunity as well as systemic immune response that may be instrumental for long term cancer cure. The goal of this observational study is to understand the effect of various radiotherapy dose per fraction, total dose and field volumes of radiation on systemic and tumor immune response in cervical cancer. The outcome of the study would be useful in improving the quality of radiation treatment and in reducing disease recurrence and improving survival in patients with cervical cancer.
Age 18 years and above.
Ability to tolerate full course of pelvic radiotherapy+/- chemotherapy +/- brachytherapy.
Ability to understand and willingness to sign an informed consent document.
Should be willing to undergo extra biopsies and blood samples collection for translational research study.
Severe medical condition impairing complete treatment delivery.
Patients with immunocompromised states or active infection.
Patients on immunosuppressive drugs for other medical conditions.
Patients who will receive immune checkpoint inhibition (ICI) therapy.
7
Trial groupsSee each trial group below.
Tata Memorial Hospital
Lead sponsor
Tata Memorial Centre
Sponsor institution